CN101962359A - Hapten, artifical antigen and antibody of enrofloxacin and preparation method as well as application thereof - Google Patents
Hapten, artifical antigen and antibody of enrofloxacin and preparation method as well as application thereof Download PDFInfo
- Publication number
- CN101962359A CN101962359A CN2010102569540A CN201010256954A CN101962359A CN 101962359 A CN101962359 A CN 101962359A CN 2010102569540 A CN2010102569540 A CN 2010102569540A CN 201010256954 A CN201010256954 A CN 201010256954A CN 101962359 A CN101962359 A CN 101962359A
- Authority
- CN
- China
- Prior art keywords
- enrofloxacin
- supernatant liquor
- preparation
- haptens
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960000740 enrofloxacin Drugs 0.000 title claims abstract description 75
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 title claims abstract description 73
- 239000000427 antigen Substances 0.000 title claims abstract description 31
- 102000036639 antigens Human genes 0.000 title claims abstract description 31
- 108091007433 antigens Proteins 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 18
- 229940124277 aminobutyric acid Drugs 0.000 claims abstract description 15
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 9
- 230000008878 coupling Effects 0.000 claims abstract description 8
- 238000010168 coupling process Methods 0.000 claims abstract description 8
- 238000005859 coupling reaction Methods 0.000 claims abstract description 8
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 5
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 4
- 239000006228 supernatant Substances 0.000 claims description 35
- 239000007788 liquid Substances 0.000 claims description 23
- 238000006243 chemical reaction Methods 0.000 claims description 16
- 239000000376 reactant Substances 0.000 claims description 11
- 102000014914 Carrier Proteins Human genes 0.000 claims description 8
- 108010078791 Carrier Proteins Proteins 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 238000001556 precipitation Methods 0.000 claims description 8
- MSWZFWKMSRAUBD-UHFFFAOYSA-N 2-Amino-2-Deoxy-Hexose Chemical compound NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 6
- 238000000502 dialysis Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 238000004062 sedimentation Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 238000012856 packing Methods 0.000 claims description 4
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 2
- 230000000890 antigenic effect Effects 0.000 claims description 2
- 150000001718 carbodiimides Chemical class 0.000 claims description 2
- 230000003203 everyday effect Effects 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 2
- 229960003405 ciprofloxacin Drugs 0.000 claims 1
- HOGDNTQCSIKEEV-UHFFFAOYSA-N n'-hydroxybutanediamide Chemical compound NC(=O)CCC(=O)NO HOGDNTQCSIKEEV-UHFFFAOYSA-N 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract description 14
- 241001465754 Metazoa Species 0.000 abstract description 9
- 239000002994 raw material Substances 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 abstract description 2
- 230000007910 cell fusion Effects 0.000 abstract description 2
- 238000005516 engineering process Methods 0.000 abstract description 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 abstract 1
- 229960002684 aminocaproic acid Drugs 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 238000005303 weighing Methods 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 238000011091 antibody purification Methods 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000024835 cytogamy Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 231100000703 Maximum Residue Limit Toxicity 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- LFHXBXASDAYCRZ-UHFFFAOYSA-N ON1C(CCC1=O)=O.[N] Chemical compound ON1C(CCC1=O)=O.[N] LFHXBXASDAYCRZ-UHFFFAOYSA-N 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010039361 Sacroiliitis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
Abstract
The invention provides a hapten, an artifical antigen and an antibody of enrofloxacin and a preparation method as well as application thereof. The preparation method comprises the following steps of: taking enrofloxacin as raw materials to react with aminobutyric acid or aminocaproic acid to produce the hapten containing four or six carbon atom arms; coupling the hapten with protein to prepare the artifical antigen through an active lipid method; mithridatizing a mice with the artifical antigen, and adopting the cell fusion technology to prepare a monoclonal antibody with high specificity to the enrofloxacin. Immunodetection established by adopting the monoclonal antibody can be used for on-site rapid detection of the enrofloxacin, and has practical significance for rapid detection on residual enrofloxacin in aquatic animals.
Description
Technical field
The invention belongs to the food safety technical field.Be specifically related to the preparation method and the application of Enrofloxacin haptens, artificial antigen and antibody.
Background technology
(Enrofloxacin, EF), its molecular formula is C to Enrofloxacin
19H
22FN
3O
3, molecular weight is 359.40, little yellow or greenish orange yellow crystalline powder, odorless, mildly bitter flavor; Meet and photochromicly fade to orange redly, its structural formula is shown in the formula (1):
Enrofloxacin is one of typical case's representative of third generation quinolones (FQs), have has a broad antifungal spectrum, toxic side effect is little, Plasma Concentration is high, long half time, dosage form are various, the drug effect price is than characteristics such as height, various Gram-negatives and positive bacteria all had powerful bacteriostatic action, all do not have characteristics such as cross resistance with penicillin, cynnematin and amino class medicine, have specific action for treatment anthrax illness.
The FQs medicine is because of it can suppress DNA of bacteria helicase, has a broad antifungal spectrum, efficient, low toxicity, tissue penetration is strong, anti-microbial effect is nearly thousand times of sulfonamides, it is chemical synthetic drug in addition, cheap, so in medical science and veterinary science, obtain widespread use very soon, especially in aquaculture, become one of most important anti-infectives.The FQs medicine is to most organs of animal body and human body and organize the untoward reaction that all has in various degree: because the FQs medicine is fat-soluble, can enter cerebral tissue by hemato encephalic barrier, suppress γ-An Jidingsuan (GABA) and produce the neural system reaction with its receptors bind.So the most common with neural damage, secondly be the damage of skin and annex thereof.Most untoward reaction symptoms are lighter, and reversible, but also have heavier even life-threatening.Experimentation on animals shows that the FQs medicine can cause cub sacroiliitis, follow the key inflammation, also can cause anaphylactic shock, feel sick, vomit, symptom and the carcinogenic character of some potential such as phlebitis, because pathogenic bacterium produce resistance, the residue problem of enrofloxacin has caused extensive concern simultaneously.The maximum residue limit(MRL) that the U.S. and European Union are defined in side in the fowl edible tissue is that Enrofloxacin and Enrofloxacin are 30 μ g/Kg; It is 50 μ g/Kg that the standard NY5070-2001 of China Ministry of Agriculture " the fishing medicine is residual in the pollution-free food fishery products limits the quantity of " regulation enrofloxacin residual is limited the quantity of.
At present, the detection of enrofloxacin residual in the aquatic animal is mainly adopted instrument detecting methods such as high performance liquid chromatography (HPLC), gas phase.Yet when using instrumental method, its sensitivity be subjected to sample purification, step such as concentrate influence very big, the measuring method existence is complicated, loaded down with trivial details, the detection flux is little, need professional and defectives such as professional skill, detection cost costliness, can not realize the rapid detection analysis of batch samples.Therefore, be necessary to develop more simple and fast detection method easily.
Immunologic detection method is one of important method of present food safety rapid detection, and it is very low to detect cost, uses simply, and the screening that is fit to a large amount of samples detects, and has brought into play vital role in food safety detection.Artificial antigen synthetic be haptens material immune analysis method set up key, for Enrofloxacin,, do not need to derive because itself contains carboxyl, all be directly to utilize this carboxyl to be connected at present therefore with protein.For example, Cai Qinren etc. have delivered paper " preparation of enrofloxacin monoclonal antibody and evaluation " (Scientia Agricultura Sinica, 2004), adopt carbodlimide method, and directly coupling carboxyl and proteinic amino have synthesized the Enrofloxacin artificial antigen; Tang Hong etc. disclose a kind of patent " enrofloxacin monoclonal antibody and application (application number 200910027793.5) ", adopt carbodlimide method with Enrofloxacin and carrier proteins BSA, HSA and OVA coupling.
But the specificity and the insight of the Enrofloxacin antibody that prior art obtains are not enough.
Summary of the invention
An object of the present invention is to fill up the deficiency of the existing detection technique of Enrofloxacin, a kind of Enrofloxacin artificial semiantigen, artificial antigen and monoclonal antibody specific are provided.
Another object of the present invention provides the preparation method of described Enrofloxacin artificial semiantigen, artificial antigen and monoclonal antibody specific.
A further object of the invention provides the application of described Enrofloxacin artificial semiantigen, artificial antigen and monoclonal antibody specific.
Purpose of the present invention is achieved by the following technical programs:
A kind of Enrofloxacin artificial semiantigen, artificial antigen and monoclonal antibody specific are provided, and described Enrofloxacin artificial semiantigen has molecular structure shown in the formula (II):
Wherein, n is-CH
2The group number, n=4 or 6, preferred n=4.
Described Enrofloxacin artificial antigen has molecular structure shown in the formula (III):
Wherein, n is-CH
2The group number, n=4 or 6, preferred n=4.
The invention provides the haptenic preparation method of described Enrofloxacin, is with Enrofloxacin and aminobutyric acid (H
2NCH
2CH
2CH
2COOH) or hexosamine (H
2NCH
2(CH
2)
4COOH) reaction generates the haptens that contains 4 or 6 carbon atom arms under NHS, DDC and DMF existence condition.
Enrofloxacin haptens synthetic route (is 4 to be example with n value in the generating structure formula):
The haptenic preparation of Enrofloxacin of the present invention may further comprise the steps:
(1) is Enrofloxacin, nitrogen N-Hydroxysuccinimide (NHS) and fat-soluble carbodiimide (DDC) to be placed beaker in 1: 1: 1 by molar ratio, and said mixture dissolved with a spot of DMF that lucifuge stirs and spends the night under the room temperature;
(2) will get A liquid through the reactant centrifuging and taking supernatant that step (1) obtains; The centrifugal 10min of the preferred 10000r/min of described centrifugally operated;
Get aminobutyric acid or hexosamine with the Enrofloxacin equimolar amount, be dissolved in a small amount of distilled water, B liquid;
(3) B liquid slowly is added in the A liquid, stirred overnight at room temperature, the centrifuging and taking supernatant liquor is transferred supernatant liquor pH value, with the sedimentation and filtration of separating out, collects supernatant liquor;
The centrifugal 10min of the preferred 10000r/min of the described centrifugally operated of step (3);
Step (3) preferably adopts saturated NaHCO
3Regulate the pH value of supernatant liquor, preferred adjust pH is 8.0～8.5;
(4) the supernatant liquor adjust pH that step (3) is made, collecting precipitation obtains Enrofloxacin haptens (CPFX-ABA).
It is 5.0～6.0 with the supernatant liquor adjust pH that step (4) preferably adopts the dilute hydrochloric acid of 1mol/L.
The preparation of artificial antigen of the present invention can be adopted active fat method, according to this area design philosophy, also can adopt other ordinary method preparations of this area.It is as follows to adopt active fat method to prepare antigenic concrete steps of the present invention:
(1) the described Enrofloxacin haptens of equimolar claim 1, DDC, NHS are dissolved among the DMF, the reaction of room temperature lucifuge is spent the night;
(2) with step (1) gained reactant centrifuging and taking supernatant liquor, supernatant liquor is joined in the borate buffer that contains carrier proteins, mixture is reacted down at 4 ℃ spend the night;
(3) treat that step (2) reaction is finished after, will react the back mixed solution dialysis tubing of packing into, dialysing obtains described artificial antigen.
Enrofloxacin monoclonal antibody specific preparation of the present invention, its concrete steps are as follows:
1) experiment selects for use the Healthy female Balb/c mouse of 8 weeks about ages as immune object, fundamental immunity dosage be 0.1～0.2mg/ only, booster immunization dosage be 03～0.5mg/ only.Artificial antigen and the abundant mixing of equivalent adjuvant, adopt the subcutaneous multi-point injection in back, every the 15d booster immunization once, in back 7～10 days of the 3rd immunity, antiserum titre and specificity are measured in afterbody blood sampling, treat that its antiserum titre and specificity are qualified after, the booster immunization that does not once contain adjuvant, the immunity back was carried out cytogamy on the 3rd day; Merge with mouse boosting cell and SP2/0 myeloma cell, obtain hybridoma, hybridoma is placed female Balb/c mouse culturing in vivo, obtain to contain the ascites of high density monoclonal antibody, and the ascites purifying is obtained the anti-enrofloxacin monoclonal antibody of high specific.
2) antibody purification adopts sad-ammonium sulfate method or Protein G/A affinitive layer purification.
The Enrofloxacin monoclonal antibody specific can be applicable to the field quick detection aspect of enrofloxacin residual in immunodetection aspect, the especially aquatic animal of enrofloxacin residual.
The invention has the beneficial effects as follows:
The present invention is raw material with the Enrofloxacin, and Enrofloxacin and aminobutyric acid or hexosamine reaction generate the haptens that contains 4 or 6 carbon atom arms, and haptens of the present invention is exposed to animal immune system more fully, strengthens the specificity and the insight of antibody; Haptens of the present invention and protein coupling are prepared artificial antigen, adopt this area routine techniques with the artificial antigen immune mouse of the present invention, the employing cell-fusion techniques makes the monoclonal antibody to the Enrofloxacin high specific, use described monoclonal antibody to set up immunodetection and can be applicable to the Enrofloxacin field quick detection, and sensitivity is higher, detectability has reached 0.05ng/mL, and the rapid detection that realizes enrofloxacin residual in the aquatic animal is had important practical significance.
Description of drawings
Fig. 1 Enrofloxacin typical curve
Embodiment
Further describe the present invention below in conjunction with the drawings and specific embodiments.Medicament such as Enrofloxacin all is a conventional commercial laboratory reagent unless stated otherwise among the embodiment.
Embodiment 1: haptens is synthetic
Take by weighing Enrofloxacin 38.6mg (about 0.1mmoL), NHS 11.5mg (about 0.1mmoL) and DDC 20.3mg (about 0.1mmoL) place round-bottomed flask, and said mixture is dissolved with a spot of DMF, under the room temperature lucifuge stir spend the night reactant;
With the centrifugal 10min of reactant 10000r/min, get supernatant, get A liquid; Get aminobutyric acid 10.3mg (0.1mmoL), be dissolved in the 1mL distilled water, be B liquid; B liquid slowly is added in the A liquid, stirred overnight at room temperature, the centrifugal 10min of 10000r/min gets supernatant liquor, uses saturated NaHCO
3Adjust pH to 8.0～8.5 have precipitation to separate out, and with sedimentation and filtration, collect supernatant liquor.With dilute hydrochloric acid (1mol/L) supernatant liquor is transferred to acidity (pH value 5.0～6.0), collecting precipitation is Enrofloxacin-aminobutyric acid haptens.
Embodiment 2: haptens is synthetic
Take by weighing Enrofloxacin 38.6mg (about 0.1mmoL), NHS 11.5mg (about 0.1mmoL) and DDC 20.3mg (about 0.1mmoL) place round-bottomed flask, and said mixture is dissolved with a spot of DMF, under the room temperature lucifuge stir spend the night reactant;
With the centrifugal 10min of reactant 10000r/min, get supernatant, get A liquid; Get aminobutyric acid 10.3mg (0.1mmoL), be dissolved in the 1mL distilled water, be B liquid; B liquid slowly is added in the A liquid, stirred overnight at room temperature, the centrifugal 10min of 10000r/min gets supernatant liquor, uses saturated NaHCO
3Adjust pH to 8.0 has precipitation to separate out, and with sedimentation and filtration, collects supernatant liquor.With dilute hydrochloric acid (1mol/L) supernatant liquor is transferred to acidity (pH value 6.0), collecting precipitation is Enrofloxacin-aminobutyric acid haptens.
Embodiment 3: haptens is synthetic
Take by weighing Enrofloxacin 38.6mg (about 0.1mmoL), NHS 11.5mg (about 0.1mmoL) and DDC 20.3mg (about 0.1mmoL) place round-bottomed flask, and said mixture is dissolved with a spot of DMF, under the room temperature lucifuge stir spend the night reactant;
With the centrifugal 10min of reactant 10000r/min, get supernatant, get A liquid; Get hexosamine 0.1mmoL, be dissolved in the 1mL distilled water, be B liquid; B liquid slowly is added in the A liquid, stirred overnight at room temperature, the centrifugal 10min of 10000r/min gets supernatant liquor, uses saturated NaHCO
3Adjust pH to 8.5 has precipitation to separate out, and with sedimentation and filtration, collects supernatant liquor.With dilute hydrochloric acid (1ol/L) supernatant liquor is transferred to acidity (pH value 6.0), collecting precipitation is Enrofloxacin-aminobutyric acid haptens.
Embodiment 4: artificial antigen synthetic
Optional taking by weighing among Enrofloxacin haptens that embodiment 1～3 prepares, the DMF (N, dinethylformamide) that each 0.1mmoL of DDC, NHS is dissolved in 2mL, the reaction of room temperature lucifuge is spent the night.With the centrifugal 10min of reactant 10000r/min, get supernatant, and it is slowly joined in the borate buffer of 5mL0.1moL/L pH9.0, its damping fluid contains carrier proteins BSA or OVA, and wherein the concentration of carrier proteins is at 20～30mg/mL, mixture reaction under 4 ℃ is spent the night, after question response was finished, the dialysis tubing of packing into was used 0.9% normal saline dialysis 3d then, change dialyzate every day 3～5 times, the solution that obtains dialysing is artificial antigen (EF-ABA-BSA or EF-ABA-OVA).
The preparation method is the same for Enrofloxacin-aminobutyric acid envelope antigen, only with the OVA of quality such as BSA changes into.
The same Enrofloxacin of the synthetic method of Enrofloxacin-hexosamine artificial antigen-aminobutyric acid artificial antigen method only changes Enrofloxacin-aminobutyric acid into equimolar Enrofloxacin-hexosamine.
Embodiment 5: the evaluation of artificial antigen:
With Enrofloxacin-aminobutyric acid artificial semiantigen is example, according to the obtained the maximum absorption of spectrophotometry haptens, carrier proteins and conjugate, calculates the coupling ratio of conjugate.Between 200～400nm, respectively raw material, BSA, OVA and conjugate ultra-violet absorption spectrum are scanned, identify whether haptens and carrier proteins coupling takes place.Estimate haptens and carrier protein couplet ratio simultaneously:
The result is as follows as calculated:
EF-ABA-BSA 22∶1 EF-ABA-OVA 19∶1
Embodiment 6: immune animal and polyclonal antibody preparation
6.1 immune animal prepares antiserum(antisera)
Experiment selects for use the Healthy female clean level Balb/c experiment mice of laboratory about conventional 8 ages in week of using as immune object, fundamental immunity dosage be 0.2mg/ only, booster immunization dosage be 0.4mg/ only.With artificial antigen and the abundant mixing of equivalent freund adjuvant, adopt the subcutaneous multi-point injection in back, every the 15d booster immunization once, in back 7～10 days of the 3rd immunity, antiserum titre and specificity are measured in afterbody blood sampling, treat that its antiserum titre and specificity are qualified after, the booster immunization that does not once contain adjuvant, the immunity back was carried out cytogamy on the 3rd day; Merge with mouse boosting cell and SP2/0 myeloma cell, obtain hybridoma, hybridoma is placed female Balb/c mouse culturing in vivo, obtain to contain the ascites of high density monoclonal antibody, and the ascites purifying is obtained the anti-enrofloxacin monoclonal antibody of high specific.
6.2 purifying antibody
Antibody purification can adopt sad-ammonium sulfate salting-out process also can adopt Protein G/A affinitive layer purification.
Embodiment 7: the Enrofloxacin enzyme-linked immunoassay method is set up
7.1 bag quilt: adopt the EF-ABA-OVA of packing to wrap quilt, bag is 1 μ g/mL envelope antigen by concentration.Every hole adds the coating buffer that 100 μ L contain envelope antigen on 96 hole enzyme plates, and 4 ℃ are spent the night.
7.2 sealing: take out bag by good enzyme plate, use washing lotion to wash plate twice, every hole adds 120 μ L confining liquids, with incubation 3h in 37 ℃ of incubators.After confining liquid is dried, put baking oven 1h.
7.3 some plate: every hole adds each the concentration standard liquid 50 μ L of Enrofloxacin through the serial dilution preparation in half good bar of sealing, adds the enzyme labelled antibody 50 μ L of 20000 times of antibody diluent dilutions again.In 37 ℃ of thermostat containers, react 30min.Use washing lotion to wash plate 6 times.
Add the sheep anti mouse horseradish peroxidase diluent 100 μ L that diluted through 1: 5000 7.4 add the every hole of ELIAS secondary antibody, be placed in 37 ℃ of thermostat containers and react 20min.Use washing lotion to wash plate 6 times.
7.5 colour developing: every hole adds substrate TMB-superoxol 100 μ L, behind 37 ℃ of colour developing 10min with 10% the H of 50 μ L
2SO
4Termination reaction.At the light absorption value of measuring on the microplate reader under the 450nm wavelength.Mapping promptly obtains typical curve according to the relation of the semilog between inhibiting rate and the Enrofloxacin concentration, sees shown in the accompanying drawing 1.
The calculating formula of described inhibiting rate is:
Inhibiting rate (%)=1-B/B
0
Wherein, B is the average light absorption value of standardized solution, B
0It is the mean light absorbency value of 0 concentration standard solution.Analysis obtains the detectability (IC of Enrofloxacin
10) be 0.05ng/mL, linearity range (IC
20～IC
80) be 0.1～8.1ng/mL.
Add rate of recovery experiment:
4 portions of chicken of weighing, every part of 2g places the 15mL centrifuge tube, and adding 0,20,100,600 μ L concentration respectively in 4 centrifuge tubes is the EF standard substance of 100ng/mL, and then chicken contains that EF concentration is respectively 0,1,5,30ng/g in 4 centrifuge tubes, vibration 2min.In centrifuge tube, add a small amount of PBS again, vortex vibration 5min, lucifuge leaves standstill 15min, adds the 4mL PBS 5min that fully vibrates, and boils 10min in the boiling water, and the centrifugal 10min of 6000r/min collects supernatant liquor.Add an amount of normal hexane in the supernatant liquor that extracts, subnatant is collected in extraction degreasing 3 times; Be settled to 6mL.Be settled to 6mL.Detect with Enrofloxacin artificial antigen of the present invention and antibody.
Experimental result see Table 1 and table 2 shown in:
Table 1 Enrofloxacin ELISA basic parameter
Table 2 direct competitive ELISA detects actual sample and adds the rate of recovery
By table 1 and table 2 as can be known, the Enrofloxacin artificial semiantigen that the inventive method prepares, antigen and antibody sensitivity are higher, sensing range 0.1～8.1ng/mL, detectability has reached 0.05ng/mL, the rate of recovery reaches 103～122%, and the variation coefficient has produced good effect 3.8～13.2.
Claims (10)
1. Enrofloxacin artificial semiantigen, it is characterized in that it being to obtain with Enrofloxacin and aminobutyric acid or hexosamine prepared in reaction under NHS, DDC and DMF existence condition, described haptens contains 4 or 6 carbon atom arms, has molecular structure shown in the formula (II):
Wherein, n is-CH
2The group number, n=4 or 6.
2. according to the described Enrofloxacin artificial semiantigen of claim 1, it is characterized in that n=4.
3. the preparation method of claim 1 or 2 described Enrofloxacin artificial semiantigens is characterized in that may further comprise the steps:
(1) is Enrofloxacin, N-hydroxy-succinamide and fat-soluble carbodiimide to be placed reaction vessel in 1: 1: 1 by molar ratio, and said mixture dissolved with a spot of DMF that lucifuge stirs and spends the night under the room temperature;
(2) will get A liquid through the reactant centrifuging and taking supernatant that step (1) obtains;
Aminobutyric acid or the hexosamine got with the Enrofloxacin equimolar amount are dissolved in a small amount of distilled water, B liquid;
(3) B liquid slowly is added in the A liquid, stirred overnight at room temperature, the centrifuging and taking supernatant liquor, transferring supernatant liquor is alkalescence, with the sedimentation and filtration of separating out, collects supernatant liquor;
(4) supernatant liquor that step (3) is made transfers to acidity, and collecting precipitation obtains the Enrofloxacin haptens.
4. preparation method according to claim 3 is characterized in that the described accent supernatant liquor of step (3) is that alkalescence is that supernatant liquor pH value is adjusted to 8.0～8.5; The described accent supernatant liquor of step (4) is that acidity is that supernatant liquor pH value is adjusted to 5.0～6.0;
5. Enrofloxacin artificial antigen is characterized in that it being that claim 1 or 2 described Enrofloxacin haptens and protein coupling are prepared; Have molecular structure shown in the formula (III):
Wherein, n is-CH
2The group number, n=4 or 6; Preferred n=4.
6. the preparation method of the described Enrofloxacin artificial antigen of claim 4 is characterized in that it being to adopt active fat method with described Enrofloxacin haptens and protein coupling.
7. preparation method according to claim 6 is characterized in that may further comprise the steps:
(1) will wait the described Enrofloxacin haptens of mole, DDC, NHS to be dissolved among the DMF, the reaction of room temperature lucifuge is spent the night;
(2) with step (1) gained reactant centrifuging and taking supernatant liquor, supernatant liquor is joined in the borate buffer that contains carrier proteins, mixture reaction spends the night;
(3) treat that step (2) reaction is finished after, will react the back mixed solution dialysis tubing of packing into, dialysing obtains described artificial antigen.
8. preparation method according to claim 7 is characterized in that the described carrier proteins of step (2) is BSA or OVA, and the concentration of carrier proteins is at 20～30mg/mL; Described temperature of reaction is 4 ℃.
9. preparation method according to claim 7 is characterized in that the described dialysis of step (3) adopted 0.9% normal saline dialysis 3 days, changes dialyzate every day 3～5 times.
10. described antigenic application of claim 5 is characterized in that being applied to prepare Enrofloxacin antibody or Ciprofloxacin immunodetection aspect.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010256954 CN101962359B (en) | 2010-08-17 | 2010-08-17 | Hapten, artifical antigen and antibody of enrofloxacin and preparation method as well as application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010256954 CN101962359B (en) | 2010-08-17 | 2010-08-17 | Hapten, artifical antigen and antibody of enrofloxacin and preparation method as well as application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101962359A true CN101962359A (en) | 2011-02-02 |
| CN101962359B CN101962359B (en) | 2013-05-01 |
Family
ID=43515427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010256954 Expired - Fee Related CN101962359B (en) | 2010-08-17 | 2010-08-17 | Hapten, artifical antigen and antibody of enrofloxacin and preparation method as well as application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101962359B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102643341A (en) * | 2012-03-30 | 2012-08-22 | 苏州博源医疗科技有限公司 | 6-methylmercaptopurine (6-MMP) immunogen and 6-MMP detection reagent |
| CN104388392A (en) * | 2014-10-30 | 2015-03-04 | 苏州大学 | Enrofloxacin monoclonal antibody as well as preparation method and application thereof |
| CN106083815A (en) * | 2016-07-04 | 2016-11-09 | 北京明日达科技发展有限责任公司 | A kind of lomefloxacin hapten preparation method and applications |
| CN106083890A (en) * | 2016-07-04 | 2016-11-09 | 北京明日达科技发展有限责任公司 | A kind of ofloxacin hapten preparation method and applications |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101565690A (en) * | 2009-05-21 | 2009-10-28 | 泰州市蛋白质工程研究院 | Enrofloxacin monoclonal antibody and application |
-
2010
- 2010-08-17 CN CN 201010256954 patent/CN101962359B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101565690A (en) * | 2009-05-21 | 2009-10-28 | 泰州市蛋白质工程研究院 | Enrofloxacin monoclonal antibody and application |
Non-Patent Citations (2)
| Title |
|---|
| 宓晓黎等: "恩诺沙星免疫抗原的制备与鉴定", 《中国动物检疫》, vol. 27, no. 6, 1 June 2010 (2010-06-01), pages 43 - 45 * |
| 隋建新等: "恩诺沙星完全抗原的合成及其偶联条件的初步优化", 《中国食品学报》, vol. 6, no. 1, 31 March 2006 (2006-03-31), pages 167 - 172 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102643341A (en) * | 2012-03-30 | 2012-08-22 | 苏州博源医疗科技有限公司 | 6-methylmercaptopurine (6-MMP) immunogen and 6-MMP detection reagent |
| CN102643341B (en) * | 2012-03-30 | 2014-04-09 | 苏州博源医疗科技有限公司 | 6-methylmercaptopurine (6-MMP) immunogen and 6-(MMP) detection reagent |
| CN104388392A (en) * | 2014-10-30 | 2015-03-04 | 苏州大学 | Enrofloxacin monoclonal antibody as well as preparation method and application thereof |
| CN104388392B (en) * | 2014-10-30 | 2017-07-18 | 苏州大学 | A kind of enrofloxacin monoclonal antibody and its preparation method and application |
| CN106083815A (en) * | 2016-07-04 | 2016-11-09 | 北京明日达科技发展有限责任公司 | A kind of lomefloxacin hapten preparation method and applications |
| CN106083890A (en) * | 2016-07-04 | 2016-11-09 | 北京明日达科技发展有限责任公司 | A kind of ofloxacin hapten preparation method and applications |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101962359B (en) | 2013-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101962358B (en) | Ciprofloxacin hapten, artificial antigen and antibody and preparation method and application thereof | |
| CN101865924B (en) | Method for detecting fumonisins based on immuno-magnetic bead combined enzyme-linked immunosorbent assay | |
| CN102174474B (en) | Sildenafil monoclonal antibody and colloidal gold chromatography test strip used for detecting sildenafil | |
| CN101921731B (en) | Monoclonal antibody of fluoroquinolone medicines as well as preparation method and application thereof | |
| CN101799472A (en) | Diethylstilbestrol detection kit and detection method | |
| CN101863981A (en) | Preparation method of anti-bisphenol A monoclonal antibody | |
| CN105044365B (en) | The preparation method of the time resolved fluoro-immunoassay test paper of detection enrofloxacin residual | |
| CN105294862B (en) | A kind of preparation method of high specific difenoconazole polyclonal antibody | |
| CN101113981A (en) | Sulfonamides direct-competition ELISA detecting reagent kit | |
| CN106084059A (en) | The general specific antibody of anti-Capsaicinoids, test strips and kitchen waste grease immunochromatography method for quick identification | |
| CN105301252B (en) | A kind of immunomagnetic beads that purification is enriched with for ochratoxin A and its preparation method and application | |
| CN106866568A (en) | Furaxone metabolite AOZ derivatizations haptens, the preparation method and applications of artificial antigen | |
| CN102746403A (en) | Standard substance universal alternate for aflatoxin detection by using ELISA, preparation method thereof, and ELISA detection method for aflatoxin | |
| CN102827076A (en) | Universal hapten, artificial antigen and broad-spectrum monoclonal antibody for fluoroquinolone medicines as well as preparation method and application of universal hapten | |
| CN101962359B (en) | Hapten, artifical antigen and antibody of enrofloxacin and preparation method as well as application thereof | |
| CN106588805A (en) | Furaltadone metabolite (AMOZ) derivatization hapten, preparation method of artificial antigen and application of artificial antigen | |
| CN105277423B (en) | A kind of immunomagnetic beads for vomitoxin enrichment purification and its preparation method and application | |
| CN106831498B (en) | Furacilin metabolite SEM derivatizations haptens, artificial antigen preparation method and applications | |
| CN104530240B (en) | Monoclonal antibody and enzyme-linked immunoassay method and kit for detecting benzodiazepine | |
| CN104744294B (en) | (α ethyl hexyls) ester hapten, artificial antigen and its preparation method for antibody of phthalic acid two and application | |
| CN109053477A (en) | A kind of preparation method and application of butralin haptens and antigen | |
| CN105646536A (en) | Ceftiofur hapten as well as colloidal gold detection device and preparation method of ceftiofur hapten | |
| CN107118159A (en) | Cistofuran metabolite AHD derivatizations haptens, the preparation method and applications of artificial antigen | |
| CN101162230A (en) | Kit for quantitative determining enrofloxacin content in food product and testing method thereof | |
| CN102608318B (en) | Monoclonal antibody, enzyme linked immunosorbent assay method and kit for detecting sulfonamides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130501 |